| scholarly article | Q13442814 |
| P50 | author | Ralf J. Ludwig | Q44533919 |
| P2093 | author name string | Vogl TJ | |
| Kaufmann R | |||
| Herzog C | |||
| Zollner TM | |||
| Ochsendorf FR | |||
| Boehncke WH | |||
| Rostock A | |||
| Thaci D | |||
| P2860 | cites work | Coronary Calcification, Coronary Disease Risk Factors, C-Reactive Protein, and Atherosclerotic Cardiovascular Disease Events | Q22252406 |
| Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial | Q28182487 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. | Q30310323 | ||
| Analysis of coronary calcifications versus Framingham and PROCAM risk assessment in patients with a first myocardial infarction | Q33227882 | ||
| Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders? | Q35057327 | ||
| The impact of the inflammatory response on coagulation | Q35928638 | ||
| Psoriasis and occlusive vascular disease | Q41043440 | ||
| Psoriasis causes as much disability as other major medical diseases | Q41686702 | ||
| Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients | Q43813250 | ||
| Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden | Q43910798 | ||
| Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients | Q44451311 | ||
| Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules | Q47758280 | ||
| Heart rate adaptive optimization of spatial and temporal resolution for electrocardiogram-gated multislice spiral CT of the heart. | Q52051522 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risk factor | Q1475848 |
| P304 | page(s) | 271-276 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | British Journal of Dermatology | Q4970191 |
| P1476 | title | Psoriasis: a possible risk factor for development of coronary artery calcification. | |
| P478 | volume | 156 |
| Q90018009 | A clinical prescription for heart health in midlife women |
| Q34089816 | A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs |
| Q82100704 | A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis |
| Q37892623 | A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis |
| Q60683249 | Abordaje integral de la comorbilidad del paciente con psoriasis |
| Q37831388 | Adipokines and psoriasis |
| Q47261263 | Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. |
| Q51312247 | Are all patients with psoriasis at increased risk for coronary artery disease? |
| Q36885064 | Assessment of adiposity in psoriatic patients by dual energy X-ray absorptiometry compared to conventional methods |
| Q88979554 | Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study |
| Q35934076 | Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan |
| Q35135113 | Attributable risk estimate of severe psoriasis on major cardiovascular events |
| Q47130996 | Cardiogoniometry in psoriatic patients and its comparison with a control group. |
| Q47218445 | Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis |
| Q82622816 | Cardiometabolic comorbidities and the approach to patients with psoriasis |
| Q37145684 | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| Q38076496 | Cardiovascular aspects of psoriasis: an updated review |
| Q35564655 | Cardiovascular comorbiditiy in psoriasis |
| Q34638027 | Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives |
| Q34253312 | Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. |
| Q39368379 | Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities |
| Q36110025 | Chronic skin-specific inflammation promotes vascular inflammation and thrombosis |
| Q38058361 | Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. |
| Q34140480 | Comorbidities and cardiovascular risk factors in patients with psoriasis |
| Q39188717 | Complement C3 as a marker of cardiometabolic risk in psoriasis |
| Q33296076 | Cost-effectiveness of psoriasis therapy with etanercept in Germany |
| Q22306446 | Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity |
| Q46611279 | Dimethylfumarate Impairs Neutrophil Functions |
| Q35854188 | Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study |
| Q38178202 | Does treatment of psoriasis reduce the risk of cardiovascular disease? |
| Q39793030 | Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study |
| Q39033915 | Endothelial cells are highly heterogeneous at the level of cytokine-induced insulin resistance |
| Q57526166 | Epicardial adipose tissue and coronary artery calcification in psoriasis patients |
| Q54518432 | Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis. |
| Q39248068 | Future diagnosis, today's treatment - cardiomyopathy in the course of psoriasis: a case report. |
| Q54344172 | Haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting lecithin-cholesterol acyltransferase activity. |
| Q64093737 | Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies |
| Q89495120 | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
| Q52657156 | Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors. |
| Q37621976 | Impaired heart rate recovery indices in psoriasis patients |
| Q37283640 | Incidence of psoriasis in children: a population-based study |
| Q57298482 | Increase in coronary atherosclerosis severity and the prevalence of coronary artery mixed plaques in patients with psoriasis |
| Q39957189 | Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. |
| Q36914874 | Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis |
| Q37987473 | Inflammation, atherosclerosis, and psoriasis. |
| Q37944171 | Investigation of latent tuberculosis infection in patients with psoriasis who are candidate for receiving immunobiological drugs. |
| Q53811311 | Links and risks associated with psoriasis and metabolic syndrome. |
| Q37779736 | Lipid disturbances in psoriasis: an update. |
| Q37428743 | Management of cardiovascular disease risk in chronic inflammatory disorders |
| Q37961072 | Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement |
| Q82622823 | Managing comorbidities in psoriasis |
| Q34409690 | Metabolic syndrome and its components in patients with psoriasis |
| Q36897095 | Metabolic syndrome in patients with psoriatic disease. |
| Q38125279 | Molecular biology of atherosclerosis |
| Q84651042 | Mortality in Psoriatic Arthritis – A Single-center Study from the UK |
| Q37027264 | National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. |
| Q36879686 | Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review |
| Q46217168 | PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. |
| Q90567424 | Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children |
| Q33951592 | Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database |
| Q85743931 | Perspective: Don't be superficial |
| Q28730205 | Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries |
| Q45249524 | Prevalence and extent of subclinical atherosclerosis in patients with psoriasis |
| Q39106788 | Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink |
| Q38808623 | Prevalence of coronary artery calcification in Japanese patients with psoriasis: A close correlation with bilateral diagonal earlobe creases |
| Q50553367 | Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. |
| Q56115291 | Psoriasis |
| Q64058521 | Psoriasis Pathogenesis and Treatment |
| Q37191317 | Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients |
| Q47579608 | Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores |
| Q33835705 | Psoriasis and cardiovascular risk: strength in numbers |
| Q34418506 | Psoriasis and comorbidities: links and risks |
| Q33867611 | Psoriasis and hypertension severity: results from a case-control study |
| Q37102789 | Psoriasis and metabolic disease: epidemiology and pathophysiology |
| Q57260319 | Psoriasis and risk of heart failure: a nationwide cohort study |
| Q48102426 | Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink |
| Q35168945 | Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature |
| Q40597678 | Psoriasis as an Independent Risk Factor for Cardiovascular Disease: An Epidemiologic Analysis Using a National Database |
| Q46838241 | Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. |
| Q37607422 | Psoriasis comorbidities |
| Q50552445 | Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. |
| Q43693973 | Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study |
| Q46966587 | Psoriasis patients show signs of insulin resistance |
| Q58785751 | Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows |
| Q37224763 | Psoriasis--new insights into pathogenesis and treatment |
| Q48708208 | Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? |
| Q36520300 | Psoriasis: it's more than just the skin |
| Q58004010 | Quoi de neuf en dermatologie clinique ? |
| Q99238702 | Recommendation for the Management of Spondyloarthritis Patients in Kuwait |
| Q38845758 | Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis |
| Q46977102 | Relationship between parathyroid hormone and subclinical myocardial dysfunction in patients with severe psoriasis. |
| Q37632485 | Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review |
| Q36515160 | Risk and predictors of cardiovascular disease in psoriasis: a population-based study |
| Q52888818 | S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. |
| Q36326833 | Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study |
| Q52314887 | Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. |
| Q35171276 | Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study |
| Q39803888 | Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial |
| Q37987268 | The concept of psoriasis as a systemic inflammation: implications for disease management |
| Q39158398 | The effect of tumour necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: A retrospective study |
| Q49404216 | The prevalence of cardiovascular diseases risk factors associated with psoriasis in Saudi Arabia |
| Q33831094 | The risk of stroke in patients with psoriasis |
| Q37831821 | The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases |
| Q33817057 | The role of nkx2.5 in keratinocyte differentiation |
| Q37766229 | The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities |
| Q34449302 | Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. |
| Q37081486 | Update on the natural history and systemic treatment of psoriasis |
| Q30250110 | Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms |
| Q83240744 | Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk |
| Q37118037 | Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center |
| Q47203093 | Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis |
| Q84033687 | [A decade of biologics in dermatology] |
| Q83200986 | [Co-morbidities in psoriasis vulgaris] |
| Q87233775 | [Comorbidities in psoriatic arthritis] |
| Q84441860 | [Current topics in psoriasis] |
| Q80703193 | [Psoriasis, a systemic disease?] |
| Q81817286 | [Severe psoriasis: beyond the skin, what are the risks of not treating the disease?] |
| Q90173138 | [The skin and rheumatism] |
Search more.